Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.
As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
Location: United States, New York
Employees: 11-50
Total raised: $160M
Founded date: 2019
Investors 7
| Date | Name | Website |
| - | Verve Vent... | verve.vc |
| - | Future Ven... | future.ven... |
| - | Longevity ... | longevity.... |
| - | Korify Cap... | korifycapi... |
| - | Longevity ... | lvf.vc |
| - | Catalio Ca... | cataliocap... |
| - | Subversive | subversive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.10.2021 | Series C | $100M | - |
| 11.02.2021 | - | $60M | - |
Mentions in press and media 9
| Date | Title | Description |
| 19.05.2022 | Can We Fix Ovarian Aging? Here Is One Startup Up For The Task! | Concept of a healthy female reproductive system. getty |
| 28.10.2021 | Cambrian Biopharma Raises $100M in Series C Funding | Cambrian Biopharma, a New York-based biotechnology company, raised $100M in Series C funding. The round was led by Anthos Capital and SALT Fund with participation from Apeiron Investment Group, Future Ventures and Moore Capital. The company... |
| 26.10.2021 | Cambrian Biopharma Closes $100 Million Series C to Advance Healthspan-boosting Therapeutics to the Clinic | NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Cambrian Biopharma, a multi-asset longevity biotech, today announced the close of an oversubscribed Series C financing, which raised $100 million. The financing was co-led by Anthos Capital and SALT F... |
| 26.10.2021 | Meet 20 (small) companies looking to save the future of ESG | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Small things can make a big difference. Paid Content Commerce content and the power of the partne... |
| 26.10.2021 | Meet 20 (small) companies looking to save the future of ESG | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Small things can make a big difference. Paid Content How health and wellness fuel success at iHer... |
| 09.02.2021 | SENSEI BIOTHERAPEUTICS, INC. Cambrian Biopharma : announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strateg... | NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Cambrian Biopharma, a Distributed Drug Discovery Company (DisCo), announced that it has raised $60 million in private financing to develop medicines to extend healthy lifespan. Cambrian is a multi-asse... |
| 09.02.2021 | Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy | |
| 09.02.2021 | Cambrian Biopharma : announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy | NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Cambrian Biopharma, a Distributed Drug Discovery Company (DisCo), announced that it has raised $60 million in private financing to develop medicines to extend healthy lifespan. Cambrian is a multi-asse... |
| 09.02.2021 | Cambrian Biopharma Raises $60M | Cambrian Biopharma, a Distributed Drug Discovery Company (DisCo), announced that it has raised $60 million in private financing to develop medicines to extend healthy lifespan. Cambrian is a multi-asset biotechnology company that combines t... |